Over the past few days, medtech's biggest names gathered in San Francisco for the Transcatheter Cardiovascular Therapies (TCT ...

Jefferies and Wolfe Research both upgraded Edwards Lifesciences EW) with Jefferies citing recent strong data for the SAPIEN ...

Edwards Lifesciences has raised its fiscal year (FY25) guidance to between $2.56 to $2.62 per share after achieving better ...

Ullem, who has held the position for more than a decade, will transition to an advisory role after his replacement is named by mid-2026.

Seven-year follow-up data show that transcatheter aortic-valve replacement (TAVR) and surgical aortic-valve replacement have ...

National Medicare coverage paves the way for a larger patient population to access the blood pressure treatment, which gained ...

Trials from Edwards, Philips and Penumbra were among the most-watched studies at the annual cardiovascular meeting.

A Medtronic hypertension procedure that can provide last-resort treatment for a condition that affects nearly half of all U.S ...

Edwards Lifesciences beat Wall Street estimates for third-quarter results on Thursday, driven by strong demand for its artificial heart valves and other medical devices, with shares rising about 3% in ...